Background: Deviation in level of intrinsic neural activity (ongoing brain signals recorded with EEG/MEG) is observed in psychosis. Neurophysiological models have proposed this physiological indicator as a genetically mediated core deviation in psychosis. Translational models of intrinsic activity deviations promise to identifying multiple distinct physiological mechanisms for psychosis manifestation. Intrinsic activity deviations may masquerade as higher levels of neural response in sensory cortices, but ultimately may lead to poor signal-to-noise ratios, particularly when psychosis cases are required to identify stimulus salience. Why do we not hear more about intrinsic activity as a core biomarker for any psychosis variation? An explanation is provided by the current project. The Bipolar-Schizophrenia Network for Intermediate Phenotypes (B-SNIP) published a means for categorizing psychoses by neurobiological homology via use of multiple biomarkers (psychosis Biotypes) rather than by clinical features. B-SNIP demonstrated the superiority of Biotypes versus DSM diagnoses for capturing neurobiological similarity through multiple external validating measures (social functioning, measures of brain volume from structural magnetic resonance images, clinical diagnoses and biomarker features among first-degree relatives). Independent analyses since the initial publication have provided additional support for the usefulness of psychosis Biotypes. Methods: For this project, we analyzed ongoing neural activity from 64 EEG sensors during 150 intervals of 10 sec duration from over 1450 B-SNIP subjects. These data (never before published) were from the intertrial interval (ITI) of an auditory paired-stimuli task used in Biotypes construction (these ITI data themselves were not used). Although the subjects were engaged in a task (counting the number of stimulus pairs), the data used here were not part of the task itself. Data were evaluated for single trial power (estimate of neural response strength on individual trials) as a function of frequency of neural oscillations (from 2-50 Hz) over the whole head. Data were then averaged over single trials to yield an estimate of the overall strength of nonspecific (unrelated to sensory processing) neural activity. Results: When evaluated by DSM diagnoses (schizophrenia, schizoaffective disorder, bipolar disorder), the 95% confidence intervals for all groups overlapped the healthy group means across all frequencies. When considered by psychosis Biotypes, differences were obvious and statistically significant. In comparison to healthy persons, Biotype-2 probands (the most neurophysiologically activated subgroup in previous analyses) were notably high on nonspecific neural activity, and Biotype-1 probands (the most cognitively and neurophysiologically compromised subgroup in previous analysis) were notably low. Group separations on this metric were better than those obtained with original intrinsic EEG measure used in psychosis Biotypes construction, indicating this more pure intrinsic activity measure is capturing a meaningful component of Biotype neurophysiology. This was true across a range of oscillatory frequencies for the probands. The first-degree relatives of the Biotype probands showed similar patterns, although higher frequency oscillations (above 20 Hz) better differentiated relatives from healthy persons. Discussion: Intrinsic activity deviation is a promising biomarker for translational research programs aimed at differential treatment development, but using DSM psychosis diagnoses would obscure its importance for understanding psychosis.
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Background: Recently, we showed that assumptions from complex system theory seem applicable in the field of psychiatry. This means that indicators of critical slowing down in the system signal the risk for a critical transition in the near future. In the current study we wanted to explore whether the principle of critical slowing down may also be informative to anticipate on the type of symptoms that individuals are most likely to develop. This is relevant as it may lead to personalized prediction of risk of whether adolescents with mixed complaints are most likely to develop either depression, anxiety, somatic or psychotic symptoms in the near future. For example, we hypothesized that critical slowing down in feeling 'suspicious' more strongly indicates risk for a future transition to psychotic symptoms, while critical slowing down in feeling 'down' more strongly indicates risk for a transition to depressive symptoms. Methods: We examined this in a population of adolescents (most between 15 and 18 years) as adolescents are an at-risk group for the development of psychopathology. At baseline experience sampling was performed for 6 days, 10 measurements a day. Affect items were used to assess autocorrelation as an indicator of 'critical slowing down' of the system. At baseline and follow-up SCL-90 questionnaires were administered. In total, 147 adolescents participated both in baseline and follow-up measures and showed increases in at least one of the defined symptom dimensions. We examined whether autocorrelation was positively associated with the size of symptom transition and whether different type of transitions (in depression, anxiety etc.) were differentially predicted by autocorrelations in specific affect states. Results: The analyses were done very recently, and findings have not been presented before. We found both shared and specific indicators of risk in the development for transition to various symptom dimensions. First, autocorrelation in 'feeling suspicious' appeared to be the strongest signal for all assessed psychopathology dimensions (SCL-90 depression: std beta: 0.185; p <0.001; SCL-90 anxiety: std beta: 0.093; p=0.006; SCL-90 interpersonal sensitivity: std beta: 0.176, p<0.001). Second, we found that the combination of 'feeling suspicious' and the affect with the secondhighest autocorrelation together predicted the precise type of symptom transition. Thus, the combination of feeling suspicious (std beta: 0.185; p<0.001) and down (std beta: 0.108; p=0.001) predicted larger increases in depressive symptoms one year later on the SCL-90, while the combination of feeling suspicious (std beta: 0.093; p=0.006) with feeling anxious (std beta: 0.086; p=0.014) predicted larger increases in anxiety symptoms a year later on the SCL-90. Discussion: These findings support the hypothesis that indicators of slowing down can not only be used to predict risk for a mean level shift in symptoms, but that they can also be informative for the type of symptom transitions at hand. In a next step these findings could be translated to designs measuring personalized early warnings for future direction of symptom shifts, and if successful to clinical implementation of these techniques.
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Overall Abstract: In the past decade, rapid advances in the field of neuroscience resulted in a dramatic paradigm shift in the way we understand the role
